Alterity Therapeutics Limited(ATHE)Earnings, Financials & Key Ratios
ATHE•NASDAQ
$5.49
Price updated Jul 7, 2026
AboutAlterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Show more
- Revenue$5M+35.3%
- EBITDA-$15M+25.7%
- Net Income-$12M+36.5%
- EPS (Diluted)-1.14+63.5%
- Gross Margin97.66%+3.2%
- EBITDA Margin-267.44%+45.1%
- Operating Margin-267.96%+45.1%
- Net Margin-223.35%+53.1%
- ROE-43.23%+58.6%
ATHE Price & Volume
Alterity Therapeutics Limited (ATHE) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Potential
Investment Thesis • Updated 2026Q2
VerdictNegative: The company's total lack of commercial revenue and a $12.8 million quarterly operating loss in 2026Q2 suggest that the firm remains in a high-burn
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical trial binary outcome
Key Thesis Takeaways
- Alterity Therapeutics remains a high-risk, pre-commercial biotechnology firm entirely dependent on non-recurring R&D tax incentives to offset significant clinical trial expenditures.
- The company's long-term viability hinges on the successful progression of its lead candidate, ATH434, as it currently lacks any commercial product revenue to support its $12.8 million quarterly operating loss.
- Investors should remain cautious regarding the persistent reliance on external capital, which has resulted in an accumulated deficit of $234.1 million and ongoing dilution risks.
Verdict Logic
binary-outcome phase that warrants extreme caution.
ATHE Growth Metrics
Alterity Therapeutics Limited (ATHE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years40.86%
5 Years-
3 Years2.01%
TTM-11.93%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-28.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM54.13%
Return on Capital
10 Years-57.2%
5 Years-65.83%
3 Years-69.46%
Last Year-51.74%
Peers Comparison
Key metrics vs top competitors for Alterity Therapeutics Limited (ATHE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.49 | $93.01M | -6.94 | 35.32% | -223.35% | -43.23% | — | |
| $9.68 | $506.78M | -2.14 | -92.84% | -260.92% | -49.88% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $2.71 | $251.14M | -5.02 | — | — | -38.76% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — |
Compare ATHE vs Peers
Alterity Therapeutics Limited (ATHE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ATHE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATHE Frequently Asked Questions
Alterity Therapeutics Limited (ATHE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Alterity Therapeutics Limited's revenue?
Alterity Therapeutics Limited (ATHE) reported $7.6M in revenue for fiscal year 2025. This represents a 851% increase from $0.8M in 2002.
How fast is Alterity Therapeutics Limited growing?
Alterity Therapeutics Limited (ATHE) grew revenue by 35.3% over the past year. This is strong growth.
Is ATHE profitable?
Alterity Therapeutics Limited (ATHE) reported a net loss of $34.2M for fiscal year 2025.
Dividend & Returns
What is ATHE's return on equity?
Alterity Therapeutics Limited (ATHE) has a return on equity (ROE) of -43.2%. Negative ROE indicates the company is unprofitable.
What is Alterity Therapeutics Limited's free cash flow?
Alterity Therapeutics Limited (ATHE) had negative free cash flow of $18.8M in fiscal year 2025, likely due to heavy capital investments.